Subscribe to RSS
DOI: 10.1055/s-0038-1672184
Orphan Three-Finger Toxins Bind at Tissue Factor–Factor VIIa Interface to Inhibit Factor X Activation: Identification of Functional Site by Docking
Publication History
24 May 2018
03 August 2018
Publication Date:
26 September 2018 (online)
Abstract
Three-finger toxins (3FTxs) contribute to toxicity of venomous snakes belonging to the family Elapidae. Currently, functions of a considerable proportion of 3FTxs are still unknown. Here, we describe the function of orphan group I 3FTxs consisting of four members. We also identified a new member of this group by sequencing a transcript isolated from Naja naja venom. This transcript, named najalexin, is identical to that previously described 3FTx from Naja atra venom gland, and shared high sequence identity with ringhalexin from Hemachatus haemachatus and a hypothetical protein from Ophiophagus hannah (here named as ophiolexin). The three-dimensional structure, as predicted by molecular modeling, showed that najalexin and ophiolexin share the same conserved structural organization as ringhalexin and other 3FTxs. Since ringhalexin inhibits the activation of factor X by the tissue factor–factor VIIa complex (TF-FVIIa), we evaluated the interaction of this group of 3FTxs with all components using in silico protein–protein docking studies. The binding of orphan group I 3FTxs to TF-FVIIa complex appears to be driven by their interaction with TF. They bind to fibronectin domain closer to the 170-loop of the FVIIa heavy chain to inhibit factor X activation. The docking studies reveal that functional site residues Tyr7, Lys9, Glu12, Lys26, Arg34, Leu35, Arg40, Val55, Asp56, Cys57, Cys58, and Arg65 on these 3FTxs are crucial for interaction. In silico replacement of these residues by Ala resulted in significant effects in the binding energies. Furthermore, these functional residues are not found in other groups of 3FTxs, which exhibit distinct pharmacological properties.
Keywords
extrinsic tenase complex - anticoagulant - factor VIIa–tissue factor complex inhibitor - orphan group I toxins-
References
- 1 Kini RM, Doley R. Structure, function and evolution of three-finger toxins: mini proteins with multiple targets. Toxicon 2010; 56 (06) 855-867
- 2 Kang TS, Georgieva D, Genov N. , et al. Enzymatic toxins from snake venom: structural characterization and mechanism of catalysis. FEBS J 2011; 278 (23) 4544-4576
- 3 Ogawa T, Chijiwa T, Oda-Ueda N, Ohno M. Molecular diversity and accelerated evolution of C-type lectin-like proteins from snake venom. Toxicon 2005; 45 (01) 1-14
- 4 Slowinski JB, Knight A, Rooney AP. Inferring species trees from gene trees: a phylogenetic analysis of the Elapidae (Serpentes) based on the amino acid sequences of venom proteins. Mol Phylogenet Evol 1997; 8 (03) 349-362
- 5 Afifiyan F, Armugam A, Tan CH, Gopalakrishnakone P, Jeyaseelan K. Postsynaptic alpha-neurotoxin gene of the spitting cobra, Naja naja sputatrix: structure, organization, and phylogenetic analysis. Genome Res 1999; 9 (03) 259-266
- 6 Chang L, Lin S, Huang H, Hsiao M. Genetic organization of alpha-bungarotoxins from Bungarus multicinctus (Taiwan banded krait): evidence showing that the production of alpha-bungarotoxin isotoxins is not derived from edited mRNAs. Nucleic Acids Res 1999; 27 (20) 3970-3975
- 7 Kordis D, Gubensek F. Adaptive evolution of animal toxin multigene families. Gene 2000; 261 (01) 43-52
- 8 Nakashima K, Nobuhisa I, Deshimaru M. , et al. Accelerated evolution in the protein-coding regions is universal in crotalinae snake venom gland phospholipase A2 isozyme genes. Proc Natl Acad Sci U S A 1995; 92 (12) 5605-5609
- 9 Kini RM, Chan YM. Accelerated evolution and molecular surface of venom phospholipase A2 enzymes. J Mol Evol 1999; 48 (02) 125-132
- 10 Doley R, Mackessy SP, Kini RM. Role of accelerated segment switch in exons to alter targeting (ASSET) in the molecular evolution of snake venom proteins. BMC Evol Biol 2009; 9: 146 ; doi: 10.1186/1471-2148-9-146
- 11 Sunagar K, Jackson TNW, Undheim EAB, Ali SA, Antunes A, Fry BG. Three-fingered RAVERs: Rapid Accumulation of Variations in Exposed Residues of snake venom toxins. Toxins (Basel) 2013; 5 (11) 2172-2208
- 12 Kini RM. Molecular moulds with multiple missions: functional sites in three-finger toxins. Clin Exp Pharmacol Physiol 2002; 29 (09) 815-822
- 13 Utkin YN. Three-finger toxins, a deadly weapon of elapid venom--milestones of discovery. Toxicon 2013; 62: 50-55
- 14 Pawlak J, Mackessy SP, Fry BG. , et al. Denmotoxin, a three-finger toxin from the colubrid snake Boiga dendrophila (Mangrove Catsnake) with bird-specific activity. J Biol Chem 2006; 281 (39) 29030-29041
- 15 Pawlak J, Mackessy SP, Sixberry NM. , et al. Irditoxin, a novel covalently linked heterodimeric three-finger toxin with high taxon-specific neurotoxicity. FASEB J 2009; 23 (02) 534-545
- 16 Pahari S, Bickford D, Fry BG, Kini RM. Expression pattern of three-finger toxin and phospholipase A2 genes in the venom glands of two sea snakes, Lapemis curtus and Acalyptophis peronii: comparison of evolution of these toxins in land snakes, sea kraits and sea snakes. BMC Evol Biol 2007; 7: 175
- 17 Ménez A. Functional architectures of animal toxins: a clue to drug design?. Toxicon 1998; 36 (11) 1557-1572
- 18 Tsetlin V. Snake venom alpha-neurotoxins and other ‘three-finger’ proteins. Eur J Biochem 1999; 264 (02) 281-286
- 19 Endo T, Tamiya N. Structure-function relationship of postsynaptic neurotoxins from snake venoms. In: Harvey AL. , ed. Snake Toxins. New York, NY: Pergamon Press; 1991: 165-222
- 20 Dufton MJ, Hider RC. Structure and pharmacology of elapid cytotoxins. Pharmacol Ther 1988; 36 (01) 1-40
- 21 Cervenansky C, Dajas F, Harvey AL. , et al. Fasciculins, anticholinesterase toxins from mamba venoms: biochemistry and pharmacology. In: Harvey AL. , ed. Snake Toxins. New York, NY: Pergamon Press; 1991: 303-321
- 22 de Weille JR, Schweitz H, Maes P, Tartar A, Lazdunski M. Calciseptine, a peptide isolated from black mamba venom, is a specific blocker of the L-type calcium channel. Proc Natl Acad Sci U S A 1991; 88 (06) 2437-2440
- 23 McDowell RS, Dennis MS, Louie A, Shuster M, Mulkerrin MG, Lazarus RA. ; McDowellRS. Mambin, a potent glycoprotein IIb-IIIa antagonist and platelet aggregation inhibitor structurally related to the short neurotoxins. Biochemistry 1992; 31 (20) 4766-4772
- 24 Banerjee Y, Mizuguchi J, Iwanaga S, Kini RM. Hemextin AB complex, a unique anticoagulant protein complex from Hemachatus haemachatus (African Ringhals cobra) venom that inhibits clot initiation and factor VIIa activity. J Biol Chem 2005; 280 (52) 42601-42611
- 25 Rajagopalan N, Pung YF, Zhu YZ, Wong PT, Kumar PP, Kini RM. Beta-cardiotoxin: a new three-finger toxin from Ophiophagus hannah (king cobra) venom with beta-blocker activity. FASEB J 2007; 21 (13) 3685-3695
- 26 Fry BG, Wüster W, Kini RM. , et al. Molecular evolution and phylogeny of elapid snake venom three-finger toxins. J Mol Evol 2003; 57 (01) 110-129
- 27 Barnwal B, Jobichen C, Girish VM, Foo CS, Sivaraman J, Kini RM. Ringhalexin from Hemachatus haemachatus: a novel inhibitor of extrinsic tenase complex. Sci Rep 2016; 6: 25935
- 28 Nirthanan S, Charpantier E, Gopalakrishnakone P. , et al. Candoxin, a novel toxin from Bungarus candidus, is a reversible antagonist of muscle (alphabetagammadelta) but a poorly reversible antagonist of neuronal α 7 nicotinic acetylcholine receptors. J Biol Chem 2002; 277 (20) 17811-17820
- 29 Nirthanan S, Charpantier E, Gopalakrishnakone P. , et al. Neuromuscular effects of candoxin, a novel toxin from the venom of the Malayan krait (Bungarus candidus). Br J Pharmacol 2003; 139 (04) 832-844
- 30 Parvathy VR, Chary KVR, Kini RM. , et al. Solution structure of candoxin, a novel three-finger toxin from the venom of Bungarus candidus. . ARKIVOC 2006; 15: 1-16
- 31 Kuhn P, Deacon AM, Comoso S. , et al. The atomic resolution structure of bucandin, a novel toxin isolated from the Malayan krait, determined by direct methods. Acta Crystallogr D Biol Crystallogr 2000; 56 (Pt 11): 1401-1407
- 32 Torres AM, Kini RM, Selvanayagam N, Kuchel PW. NMR structure of bucandin, a neurotoxin from the venom of the Malayan krait (Bungarus candidus). Biochem J 2001; 360 (Pt 3): 539-548
- 33 Girish VM, Kini RM. Exactin: A specific inhibitor of Factor X activation by extrinsic tenase complex from the venom of Hemachatus haemachatus . Sci Rep 2016; 6: 32036
- 34 Vonk FJ, Casewell NR, Henkel CV. , et al. The king cobra genome reveals dynamic gene evolution and adaptation in the snake venom system. Proc Natl Acad Sci U S A 2013; 110 (51) 20651-20656
- 35 Tan CH, Tan KY, Fung SY, Tan NH. Venom-gland transcriptome and venom proteome of the Malaysian king cobra (Ophiophagus hannah). BMC Genomics 2015; 16: 687
- 36 Gibbs CS, McCurdy SN, Leung LL, Paborsky LR. Identification of the factor VIIa binding site on tissue factor by homologous loop swap and alanine scanning mutagenesis. Biochemistry 1994; 33 (47) 14003-14010
- 37 Paborsky LR, Law VS, Mao CT, Leung LLK, Gibbs CS. A peptide derived from a tissue factor loop region functions as a tissue factor--factor VIIa antagonist. Biochemistry 1995; 34 (46) 15328-15333
- 38 Ruf W, Miles DJ, Rehemtulla A, Edgington TS. Tissue factor residues 157-167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 1992; 267 (31) 22206-22210
- 39 Ruf W, Kelly CR, Schullek JR. , et al. Energetic contributions and topographical organization of ligand binding residues of tissue factor. Biochemistry 1995; 34 (19) 6310-6315
- 40 Dickinson CD, Kelly CR, Ruf W. Identification of surface residues mediating tissue factor binding and catalytic function of the serine protease factor VIIa. Proc Natl Acad Sci U S A 1996; 93 (25) 14379-14384
- 41 Petrovan RJ, Ruf W. Role of residue Phe225 in the cofactor-mediated, allosteric regulation of the serine protease coagulation factor VIIa. Biochemistry 2000; 39 (47) 14457-14463
- 42 Choudhury M, McCleary RJR, Kesherwani M, Kini RM, Velmurugan D. Comparison of proteomic profiles of the venoms of two of the ‘Big Four’ snakes of India, the Indian cobra (Naja naja) and the common krait (Bungarus caeruleus), and analyses of their toxins. Toxicon 2017; 135: 33-42
- 43 Gouet P, Robert X, Courcelle E. ESPript/ENDscript: Extracting and rendering sequence and 3D information from atomic structures of proteins. Nucleic Acids Res 2003; 31 (13) 3320-3323
- 44 Tamura K, Stecher G, Peterson D, Filipski A, Kumar S. MEGA6: Molecular Evolutionary Genetics Analysis version 6.0. Mol Biol Evol 2013; 30 (12) 2725-2729
- 45 Laskowski RA, MacArthur MW, Moss DS. , et al. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993; 26: 283-291
- 46 Comeau SR, Gatchell DW, Vajda S, Camacho CJ. ClusPro: a fully automated algorithm for protein-protein docking. Nucleic Acids Res 2004; 32 (Suppl. 02) W96-W99
- 47 Polak E, Ribiere G. Revenue Francaise Informat. Recherche Operationelle. 1969; 16: 35
- 48 Pillet L, Trémeau O, Ducancel F. , et al. Genetic engineering of snake toxins. Role of invariant residues in the structural and functional properties of a curaremimetic toxin, as probed by site-directed mutagenesis. J Biol Chem 1993; 268 (02) 909-916
- 49 Antil-Delbeke S, Gaillard C, Tamiya T. , et al. Molecular determinants by which a long chain toxin from snake venom interacts with the neuronal alpha 7-nicotinic acetylcholine receptor. J Biol Chem 2000; 275 (38) 29594-29601
- 50 Fiore MM, Neuenschwander PF, Morrissey JH. The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa. J Biol Chem 1994; 269 (01) 143-149
- 51 Sorensen AB, Madsen JJ, Svensson LA. , et al. Molecular basis of enhanced activity in factor VIIa-trypsin variants conveys insights into tissue factor-mediated allosteric regulation of factor VIIa activity. J Biol Chem 2016; 291 (09) 4671-4683
- 52 Banner DW, D'Arcy A, Chène C. , et al. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 1996; 380 (6569): 41-46
- 53 Pike AC, Brzozowski AM, Roberts SM, Olsen OH, Persson E. Structure of human factor VIIa and its implications for the triggering of blood coagulation. Proc Natl Acad Sci U S A 1999; 96 (16) 8925-8930